Anuh Pharma Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Company has a healthy return on capital (ROCE) of 21.8%
- Latest quarter profit grew 37.7% YoY, showing strong momentum
- Company has been maintaining a healthy dividend payout of 36.6%
- Company generates healthy free cash flow
- Company has a consistent dividend-paying track record
CONS
- Operating cash flow has been negative in recent years
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.32x)
- Valuation is stretched - P/E of 21.5 is well above its own 5-year median (10.2)
- Company has delivered a poor profit growth of 7.6% over past five years
- Operating margins have contracted to 7.4% from 10.9%
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| ANUHPHR | 94.62 | 21.47 | 948.32 | 1.59 | 114.25 | 1276.51 | 1938.10 | 939.31 | 16.02 | 8.40 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 161 | 150 | 172 | 164 | 138 | 166 | 160 | 198 | 186 | 186 | 197 | 202 | 1,938 | |
| 148 | 132 | 148 | 145 | 127 | 149 | 145 | 179 | 176 | 174 | 180 | 182 | 1,800 | |
| Operating Profit | 14 | 18 | 24 | 19 | 11 | 17 | 15 | 19 | 10 | 12 | 17 | 20 | 139 |
| OPM % | 8.65% | 12.01% | 13.94% | 11.73% | 7.66% | 10.17% | 9.27% | 9.42% | 5.52% | 6.39% | 8.52% | 9.84% | 7.15% |
| 3 | 2 | 4 | 3 | 4 | 3 | 1 | 1 | 3 | 1 | 4 | -1 | 31 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 24 |
| Profit before Tax | 15 | 18 | 25 | 20 | 12 | 18 | 13 | 17 | 11 | 10 | 18 | 16 | 169 |
| Tax % | 23.75% | 22.60% | 24.46% | 22.11% | 22.49% | 17.32% | 22.00% | 27.89% | 24.20% | 23.29% | 24.57% | 24.74% | 32.51% |
| Net Profit | 12 | 14 | 19 | 15 | 10 | 15 | 10 | 12 | 8 | 8 | 13 | 12 | 114 |
| 2.35 | 2.76 | 3.81 | 3.06 | 1.90 | 1.50 | 1.03 | 1.24 | 1.66 | 0.76 | 1.34 | 1.17 | 1.14 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 772 | 779 | |
| 183 | 220 | 291 | 284 | 387 | 439 | 476 | 571 | 600 | 714 | 717 | |
| Operating Profit | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 57 | 62 |
| OPM % | 11.00% | 7.70% | 9.34% | 7.57% | 10.45% | 9.75% | 9.82% | 11.71% | 9.30% | 7.44% | 8.01% |
| 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | 9 | 9 | 7 | |
| Interest | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 | 9 | 11 | 11 |
| Profit before Tax | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 | 61 | 54 | 60 |
| Tax % | 27.32% | 29.49% | 27.89% | 25.32% | 26.24% | 21.88% | 23.78% | 23.31% | 22.38% | 24.30% | 26.63% |
| Net Profit | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 41 | 44 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 5.67 | 6.10 | 7.22 | 11.98 | 9.45 | 4.10 | — |
| Dividend Payout % | 31.24% | 41.73% | 29.49% | 48.17% | 26.43% | 28.70% | 27.70% | 20.86% | 15.87% | 36.63% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 9%
- 5 Years:
- 12%
- 3 Years:
- 14%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 5%
- 5 Years:
- 8%
- 3 Years:
- 4%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- 9%
RETURN ON EQUITY
- 10 Years:
- 15%
- 5 Years:
- 16%
- 3 Years:
- 17%
- Last Year:
- 12%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 | 25 | 50 |
| 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 | 301 | 302 | |
| 0 | 2 | 4 | 45 | 14 | 4 | 1 | 2 | 11 | 0 | |
| Trade Payables | 42 | 52 | 59 | 105 | 120 | 122 | 153 | 141 | 157 | 188 |
| 5 | 4 | 11 | 15 | 8 | 8 | 9 | 11 | 11 | 14 | |
| Total Liabilities | 187 | 208 | 239 | 326 | 333 | 347 | 404 | 445 | 505 | 554 |
| 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | 58 | 57 | |
| Capital Work in Progress | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 | 106 | 84 | |
| 30 | 32 | 43 | 61 | 81 | 80 | 73 | 75 | 74 | 148 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 190 | 216 | 239 | |
| Cash & Bank | 6 | 8 | 11 | 3 | 20 | 16 | 7 | 8 | 20 | 8 |
| 63 | 79 | 91 | 99 | 128 | 147 | 181 | 25 | 30 | 18 | |
| Total Assets | 187 | 208 | 239 | 326 | 333 | 347 | 404 | 445 | 505 | 554 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 34 | 9 | 17 | 54 | -9 | 38 | 67 | 13 | 37 | -3 | |
| Cash from Investing | -20 | 2 | 3 | -77 | 52 | -8 | -43 | 1 | -20 | 18 |
| Cash from Financing | -4 | -5 | -7 | 22 | -33 | -19 | -12 | -9 | -5 | -26 |
| 2 | -1 | 3 | -5 | 0 | 2 | -2 | 5 | 12 | -11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-08-19 - Anuh Pharma Limited has informed the Exchange about Investor Presentation
2026-08-14 - Anuh Pharma Limited has informed the Exchange about change in Management
2026-08-14 - Anuh Pharma Limited has informed the Exchange regarding Appointment of Mr Bipin N. Shah, Mr. Arun L. Todarwal and Mr. Ankit Chande as Directors of the company.
2026-08-14 - Anuh Pharma Limited has informed the Exchange about General Updates under Regulation 30.
2026-08-14 - Anuh Pharma Limited has submitted the Exchange a copy Voting Results and Scrutinizers report of Annual General Meeting held on August 12, 2026.
2026-08-12 - Anuh Pharma Limited has informed the Exchange regarding Proceedings of 66th Annual General Meeting held on August 12, 2026
2026-08-09 - Anuh Pharma Limited has informed the Exchange about Copy of Newspaper Publication of the Unaudited financial results for the Quarter ended 30th June, 2026, published in the Financial Express in English Language and Mumbai Lakshdeep in Marathi Language on 09th June, 2026.
2026-08-07 - Anuh Pharma Limited has informed the Exchange regarding 'Adoption of Revised Policy of Related Party Transactions.'.
2026-08-07 - Anuh Pharma Limited has informed the Exchange regarding 'Request received for Withdrawal of application for reclassification of shareholding from Promoter & Promoter Group to Public Category'.
News
Recent coverage and analyst commentary for ANUHPHR
Loading news…
AI Stock Analyst
Anuh Pharma Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account